Catching up with Bristol Myers and Merck, AstraZeneca declares neoadjuvant win for PD-L1/chemo combo
When AstraZeneca started the Phase III AEGEAN trial for Imfinzi in 2018, it was, alongside several Big Pharma brethren, hoping to push the use of PD-(L)1 therapies into earlier lines of treatment.